Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks

European Neurology

Volumn 41, Issue 1, 1999, Pages 37-43

  Le Jeunne, C ^a   Pascual Gomez J ^e   Pradalier, A ^b   Titus I Albareda, F ^f   Joffroy, A ⁱ   Liano H ^g   Henry, P ^c   Lainez, J M ^h   Geraud, G ^d  

^a Hopital Laennec   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c HÔPITAL PELLEGRIN   (France)

^d CHU RANGUEIL   (France)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f Clinica Dexeus Barcelona   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ ERASME HOSPITAL   (Belgium)

Author keywords

Acute treatment; Caffeine; Calcium carbasalate; Ergotamine tartrate; Metoclopramide; Migraine

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; CARBASALATE CALCIUM; DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; PLACEBO; SUMATRIPTAN;

ADULT; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SOMNOLENCE; VOMITING;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANALGESICS; ASPIRIN; CAFFEINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERGOTAMINE; FEMALE; HUMANS; MALE; METOCLOPRAMIDE; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; PATIENT ACCEPTANCE OF HEALTH CARE; SAFETY; SLEEP STAGES; TREATMENT OUTCOME; UREA;

EID: 0032954774     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007996     Document Type: Article

References (24)

1. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R, the GRIM: A nationwide survey of migraine in France: Prevalence and clinical features in adults. Cephalalgia 1992;12: 229-237.
2. Rasmussen BK: Epidemiology of migraine. Biomed Pharmacother 1995;49:452-455.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992;267:64-69.
4. Headache Classification Committee of the International Headache Society: Diagnostic Criteria. Cephalalgia 1988;8:19-28.
5. Berde B, Cerletti A, Dengler HJ, Zoglio MA: Studies of the interaction between ergot alkaloids and xanthine derivatives; in Cochrane AL (ed): Background to Migraine. London, Heinemann, 1970, pp 80-102.
6. Wilkinson M: The treatment of acute migraine attacks. Headache 1976;15:291.
7. Thrush D: Treatment of migraine. Br Med J 1978;i:1004.
8. Volans GN: Absorption of effervescent aspirin during migraine. Br Med J 1974;4:265-269.
9. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG: Combined lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: A multicentre double-blind placebo-controlled study. Cephalalgia 1994;14:297-300.
10. Henry P, Hiesse-Provost O, Dillenschneider A, Ganry H, Insuasty J: Efficacité et tolérance de l'association of effervescente aspirine-métoclopramide dans le traitement de la crise de migraine sans aura. Essai randomisé en double aveugle contre placebo. Presse Méd 1995;24: 254-258.
11. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346: 923-926.
12. Murray FE, Hudson N, Atherton JC, Cole AT, Scheck F, Hawkey CJ: Comparison of effects of calcium carbasalate and aspirin on gaslroduodenal mucosal damage in human volunteers. Gut 1996;38:11-14.
13. Pradalier A, Guérard des Lauriers A, Scheck F, Peraudeau P, Lacoste JP, Cajfinger F: Association carbasalate calcique-métoclopramide versus dihydroergotamine dans le traitement de la crise de migraine. Pathol Biol 1995;43:806-813.
14. Waters WE: Controlled clinical trial of ergotamine tartrate. Br Med J 1970;2:325-327.
15. Ryan RE: Double-blind clinical evaluation of the efficacy and safety of ergostine-caffeine. ergotamine-caffeine and placebo in migraine headache. Headache 1970;9:212-220.
16. Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J: Acute migraine attack therapy: Comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985;5:107-113.
17. Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, Solbach P: Aborting a migraine attack: Naproxen sodium vs. ergotamine plus caffeine. Headache 1988;28:263-266.
18. Kinnunen E, Erkinjuntti T, Färkkilä M, Palomäki H, Porras J, Teirmaa H, Freudenthal Y, Andersson P: Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988;8:175-179.
19. Friedman AP, Di Serio FJ, Hwang DS: Symptomatic relief of migraine: Multicenter comparison of Cafergot® P-B, Cafergot®, and placebo. Clin Ther 1989;11:170-182.
20. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group: A randomised, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-322.
21. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J: Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979;ii:326-328.
22. Mathew NT: Dosing and administration of ergotamine tartrate and dihydroergotamine. Headache 1997;37(suppl 1):S26-S32.
23. Dahlöf C: Placebo-controlled trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-171.
24. Tfelt-Hansen P, Johnson ES: Ergotamine; in Diesen J, Tfelt-Hansen P, Welch KMA (eds): The Headaches. New York, Raven Press, 1993, pp 313-322.